奥西默替尼
谷氨酰胺
谷氨酰胺分解
程序性细胞死亡
生物
癌症研究
A549电池
癌细胞
碳水化合物代谢
细胞生长
细胞培养
葡萄糖摄取
细胞生物学
细胞
生物化学
内分泌学
细胞凋亡
癌症
胰岛素
表皮生长因子受体
受体
埃罗替尼
遗传学
氨基酸
作者
Kamal Eltayeb,Roberta R Alfieri,Claudia Fumarola,Mara A. Bonelli,Maricla Galetti,Andrea Cavazzoni,Graziana Digiacomo,Francesca Galvani,Federica Vacondio,Alessio Lodola,Marco Mor,Roberta Minari,Marcello Tiseo,Silvia La Monica,Pier Giorgio Petronini
标识
DOI:10.1016/j.bcp.2024.116161
摘要
Osimertinib, a tyrosine kinase inhibitor targeting mutant EGFR, has received approval for initial treatment in patients with Non-Small Cell Lung Cancer (NSCLC). While effective in both first- and second-line treatments, patients eventually develop acquired resistance. Metabolic reprogramming represents a strategy through which cancer cells may resist and adapt to the selective pressure exerted by the drug. In the current study, we investigated the metabolic adaptations associated with osimertinib-resistance in NSCLC cells under low glucose culture conditions. We demonstrated that, unlike osimertinib-sensitive cells, osimertinib-resistant cells were able to survive under low glucose conditions by increasing the rate of glucose and glutamine uptake and by shifting towards mitochondrial metabolism. Inhibiting glucose/pyruvate contribution to mitochondrial respiration, glutamine deamination to glutamate, and oxidative phosphorylation decreased the proliferation and survival abilities of osimertinib-resistant cells to glucose starvation. Our findings underscore the remarkable adaptability of osimertinib-resistant NSCLC cells in a low glucose environment and highlight the pivotal role of mitochondrial metabolism in mediating this adaptation. Targeting the metabolic adaptive responses triggered by glucose shortage emerges as a promising strategy, effectively inhibiting cell proliferation and promoting cell death in osimertinib-resistant cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI